UB Paderborn / Katalog / Suche / in CDI

Risk of not receiving second-line therapy is high in EGFR mt+ patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients

Annals of oncology, 2019-04, Vol.30, p.ii48-ii48

2019

Link zum Volltext

Verfügbarkeit prüfen

Risk of not receiving second-line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts

Annals of oncology, 2018-10, Vol.29, p.viii523-viii523

2018

Link zum Volltext

Verfügbarkeit prüfen

Identification of therapeutically targetable genomic alterations in a cohort of patients with CUP using a hybrid-capture based next generation sequencing assay

European journal of cancer (1990), 2016-12, Vol.69, p.S55-S55

2016

Link zum Volltext

Verfügbarkeit prüfen

1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy

Annals of oncology, 2023-10, Vol.34, p.S770-S770

2023

Link zum Volltext

Verfügbarkeit prüfen

P74.02 Treatment Patterns of EGFR mt+ NSCLC IV pts: Real World Data of the NOWEL Network

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S572-S572

2021

Link zum Volltext

Verfügbarkeit prüfen

P33.20 Evaluation of Combined Biomarker of Response to Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S413-S414

2021

Link zum Volltext

Verfügbarkeit prüfen

Treatment patterns of EGFR mt+ NSCLC IV pts: Real-world data of the NOWEL network

Annals of oncology, 2019-10, Vol.30, p.v630

2019

Link zum Volltext

Verfügbarkeit prüfen

1533P - Treatment patterns of EGFR mt+ NSCLC IV pts: Real-world data of the NOWEL network

Annals of oncology, 2019-10, Vol.30, p.v630-v630

2019

Link zum Volltext

Verfügbarkeit prüfen

1325P Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP registry real-world cohort (AIO-TRK-0315)

Annals of oncology, 2021-09, Vol.32, p.S1015-S1016

2021

Link zum Volltext

Verfügbarkeit prüfen

1246P Hybrid capture-based assays in primary diagnostics of NSCLC patients: Results from the NEOlung study

Annals of oncology, 2020-09, Vol.31, p.S807-S807

2020

Link zum Volltext

Verfügbarkeit prüfen

P1.01-82 Risk of Not Receiving 2nd Line Therapy is High in EGFR mt+ pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR mt+ pts

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S494-S495

2018

Link zum Volltext

Verfügbarkeit prüfen

163P The influence of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ patients on OS and PFS: Results of the NOWEL network

Journal of thoracic oncology, 2018-04, Vol.13 (4), p.S98-S98

2018

Link zum Volltext

Verfügbarkeit prüfen

1912TiP NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery

Annals of oncology, 2020-09, Vol.31, p.S1083-S1083

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ pts: Results of the NOWEL network

Annals of oncology, 2017-09, Vol.28, p.v486

2017

Link zum Volltext

Verfügbarkeit prüfen

152 - Identification of therapeutically targetable genomic alterations in a cohort of patients with CUP using a hybrid-capture based next generation sequencing assay

European journal of cancer (1990), 2016-12, Vol.69, p.S55-S55

2016

Link zum Volltext

Verfügbarkeit prüfen

P3.01-038 Impact on OS and PFS of 2nd and 3rd Generation TKI in EGFR Mt+ and ALK+ Patients: Results of the NOWEL Network

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S2215-S2215

2017

Link zum Volltext

Verfügbarkeit prüfen

1533PTreatment patterns of EGFR mt+ NSCLC IV pts: Real-world data of the NOWEL network

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Link zum Volltext

Verfügbarkeit prüfen

121PRisk of not receiving second-line therapy is high in EGFR mt+ patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients

Annals of oncology, 2019-04, Vol.30 (Supplement_2)

2019

Link zum Volltext

Verfügbarkeit prüfen

1447PRisk of not receiving second-line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Link zum Volltext

Verfügbarkeit prüfen

The influence of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ patients on OS and PFS: Results of the NOWEL network: 163P

Journal of thoracic oncology, 2018-04, Vol.13 (4 Suppl), p.S98-S98

2018

Link zum Volltext

Verfügbarkeit prüfen

Allow Golden Rice to save lives

Proceedings of the National Academy of Sciences - PNAS, 2021-12, Vol.118 (51)

2021

Link zum Volltext

Verfügbarkeit prüfen

3D microperfusion of mesoscale human microphysiological liver models improves functionality and recapitulates hepatic zonation

Acta biomaterialia, 2023-11, Vol.171, p.336-349

2023

Link zum Volltext

Verfügbarkeit prüfen

Opinion: Allow Golden Rice to save lives

Proceedings of the National Academy of Sciences - PNAS, 2021-12, Vol.118 (51)

2021

Link zum Volltext

Verfügbarkeit prüfen

Coexistence Rules and Regulations in the European Union

American journal of agricultural economics, 2006-12, Vol.88 (5), p.1193-1199

2006

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Risk of not receiving second-line therapy is high in EGFR mt+ patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients

Risk of not receiving second-line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts

Identification of therapeutically targetable genomic alterations in a cohort of patients with CUP using a hybrid-capture based next generation sequencing assay

1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy

P74.02 Treatment Patterns of EGFR mt+ NSCLC IV pts: Real World Data of the NOWEL Network

P33.20 Evaluation of Combined Biomarker of Response to Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer

Treatment patterns of EGFR mt+ NSCLC IV pts: Real-world data of the NOWEL network

1533P - Treatment patterns of EGFR mt+ NSCLC IV pts: Real-world data of the NOWEL network

1325P Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP registry real-world cohort (AIO-TRK-0315)

1246P Hybrid capture-based assays in primary diagnostics of NSCLC patients: Results from the NEOlung study

P1.01-82 Risk of Not Receiving 2nd Line Therapy is High in EGFR mt+ pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR mt+ pts

163P The influence of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ patients on OS and PFS: Results of the NOWEL network

1912TiP NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery

Impact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ pts: Results of the NOWEL network

152 - Identification of therapeutically targetable genomic alterations in a cohort of patients with CUP using a hybrid-capture based next generation sequencing assay

P3.01-038 Impact on OS and PFS of 2nd and 3rd Generation TKI in EGFR Mt+ and ALK+ Patients: Results of the NOWEL Network

1533PTreatment patterns of EGFR mt+ NSCLC IV pts: Real-world data of the NOWEL network

121PRisk of not receiving second-line therapy is high in EGFR mt+ patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients

1447PRisk of not receiving second-line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts

The influence of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ patients on OS and PFS: Results of the NOWEL network: 163P

Allow Golden Rice to save lives

3D microperfusion of mesoscale human microphysiological liver models improves functionality and recapitulates hepatic zonation

Opinion: Allow Golden Rice to save lives

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

Coexistence Rules and Regulations in the European Union

Suchergebnisse filtern